Luciano Costa, MD, PhD, María Victoria Mateos, MD, PhD, and Roberto Mina, MD, shared their thoughts on the use of teclistamab and CRS management earlier in multiple myeloma.
Roberto Mina, MD
Roberto Mina is an associate professor at Winship Cancer Institute of Emory University and former assistant professor at University of Turin in Italy.
Articles by Roberto Mina, MD
Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple myeloma.
Roberto Mina, MD, associate professor of hematology at the Winship Cancer Institute at Emory University, discussed the significance of the patient population of the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.
Roberto Mina, MD, discussed the significance of the early outcomes that were reported from the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.
